

Press Release

Stockholm, Sweden, June 28, 2024

Change in number of shares and votes in Mendus AB (publ)

As previously announced, the Annual General Meeting of Mendus AB (publ) ("Mendus") on May 17, 2024, resolved on a reverse share split, whereby twenty (20) existing shares were consolidated into one (1) new share.

As a result thereof, the number of shares and votes in Mendus has changed. Through the reverse share split, the number of shares in Mendus decreased from 1,007,191,573 shares to 50,359,578 shares.

As of June 28, 2024, the last trading day of the month, there was a total of 50,359,578 shares and votes in Mendus.

For more information, please contact:

Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>

This information is such information that Mendus AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (Sw. lagen om handel med finansiella instrument). The information was submitted for publication through the agency of the contact persons set out below on June 28, 2024, at 08:00 CEST.